Multi-omics, spatial omics and AI are closing the gap between tissue biology and chronic disease care
Chronic disease rarely behaves like a uniform process. In the same organ, injury, repair, fibrosis, metabolic rewiring, and immune activation can coexist in different compartments, producing clinical trajectories that look similar at the bedside but differ sharply at the tissue level. This review lays out how multi-omics, spatial omics, and artificial intelligence are being used to connect those layers of biology rather than flatten them into a single averaged signal.
The practical appeal is obvious. Bulk assays can miss the biology that matters most because they compress a lesion into one blended readout. Single-cell methods improve resolution, but they still leave a major question unanswered: why a particular cell state appears in one anatomical niche and not another, and why that location changes prognosis or treatment response. Chronic disease is not just molecular; it is territorial.
Why tissue position matters as much as molecular state
Pathology in chronic disease is shaped by where cells sit, who their neighbors are, and how the local matrix and vascular environment constrain their behavior. A fibrotic edge, an inflammatory core, and a regenerative margin may share some pathways while diverging in others. Spatial organization therefore becomes more than descriptive anatomy; it is part of disease mechanism.
One sentence captures the central problem. Averaging across tissue can erase the very signals that drive progression.
Multi-omics approaches help recover those signals by layering regulation, transcription, protein activity, and metabolism. This matters because chronic inflammation, aberrant repair, and metabolic remodeling are rarely isolated events. They reinforce one another through signaling loops, extracellular matrix changes, and shifts in cellular energy use. A tissue that appears stable at one molecular layer may already be reorganizing across several others.
Spatial omics turns anatomy into a readable disease map
Spatial omics keeps tissue architecture intact while measuring molecular activity within it. That makes it possible to define lesion topology, map interface states, and identify multicellular microenvironments that are otherwise invisible in dissociated or bulk samples. In a chronic disease setting, this can expose the niches where pathogenic programs are maintained and the margins where those programs first expand.
The review emphasizes that spatially resolved analysis can explain why similar molecular signatures produce different clinical phenotypes. Two regions may express overlapping markers but differ in cell-cell interactions, immune surveillance, matrix density, or access to nutrients and oxygen. Those contextual differences shape whether a lesion stays quiescent, spreads, or responds to therapy.
A second sentence is just as important. The same cell state can mean something different depending on where it lives in the tissue.
This is where the field moves beyond cataloging markers. Spatial data can identify recurrent microenvironmental patterns, such as pathological niches and boundary zones, and can connect them to disease stage or treatment exposure. That kind of mapping is especially valuable in chronic disease, where progression often unfolds over years and tissue remodeling accumulates in layers.
AI is most useful when it can integrate, not merely classify
Artificial intelligence enters the workflow as a bridge between molecular data, spatial information, imaging, and clinical variables. The review argues that AI may help generate disease representations that support stratification, mechanistic pattern discovery, and clinically testable prediction. In principle, that could make high-dimensional datasets usable at the point of decision-making rather than confined to exploratory research.
But the conditions are strict. Models have to be externally validated, biologically interpretable, and robust to dataset bias and domain shift. Without those safeguards, a model can look strong inside one cohort and fail as soon as it is applied to another hospital, platform, or disease stage. Chronic disease research is especially vulnerable to this problem because samples often come from heterogeneous populations, multiple tissue types, and inconsistent preanalytical workflows.
Interpretability is not an academic luxury. If a model cannot show which molecular, spatial, or imaging features drove its output, it may be difficult to distinguish a true biological signature from a technical artifact. Clinicians need models that explain why a patient is categorized a certain way, not just that a label was assigned.
Six disease domains frame the current evidence base
The review examines six representative disease domains before drawing broader conclusions about how these technologies can define molecular endotypes, map pathological niches, identify recurrent mechanistic patterns, and generate surrogate readouts for diagnosis, prognosis, and treatment stratification. Even without reducing these tools to one organ system, the logic is consistent across chronic conditions: better resolution leads to better biological assignment, and better assignment should improve clinical matching.
This approach is particularly attractive for diseases in which tissue heterogeneity drives treatment failure. A therapy may hit one molecular program but miss another that is embedded in a different niche. Spatial and multi-omics profiling can help identify those escape routes before they become clinically obvious.
Preanalytical variability remains a major barrier to deployment
The review is candid about the limitations. Preanalytical variability, inconsistency across platforms, limited external generalizability, and difficulty translating high-dimensional outputs into deployable tools all stand in the way of routine use. Those are not abstract concerns; they affect whether a result can be trusted across centers, whether it can be reproduced in follow-up studies, and whether it can influence a real treatment decision.
External validation is especially important because chronic disease cohorts are rarely homogeneous. Disease duration, treatment history, tissue sampling site, and assay platform can all alter the signal. A model that performs well in one setting may be unstable elsewhere if it has learned the quirks of the dataset rather than the biology of the disease.
The translational hurdle is equally concrete. Even the best multimodal model has limited value if its output cannot be converted into a workflow that fits pathology, imaging, or routine laboratory practice.
Mechanism-guided validation will determine clinical value
The most durable path forward is not bigger data alone, but better evidence systems. The review calls for mechanism-guided validation frameworks, scalable evidence generation, multimodal interpretability, and prospective clinical implementation. That sequence matters because high-dimensional analytics only become clinically credible when they are tied back to biology and tested in forward-looking studies.
For chronic disease research, the opportunity is substantial. Multi-omics can define what is changing, spatial omics can show where it is changing, and AI can integrate those signals into predictions that are both reusable and testable. If those layers can be aligned with robust validation, the field could move from broad descriptive profiling toward disease models that reflect actual tissue behavior.
The unresolved issue is not whether the technologies are powerful. It is whether they can be standardized enough to survive contact with real-world samples, real-world variability, and real-world clinical decision-making.